You are here: Industry Insights > Valneva

News List

Valneva's Lyme vaccine—the only active candidate out there—moves to phase 2 fiercepharma
December 20, 2018
On the back of positive phase 1 data, Valneva has started a phase 2 study on VLA15, currently the only Lyme disease vaccine candidate in active clinical development.
Emergent and Valneva's Zika vaccine clears phase 1 fiercepharma
December 11, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
mergent BioSolutions and Valneva’s Zika vaccine turns up positive early-phase data fiercepharma
December 04, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
Emergent and Valneva's Zika vaccine clears phase 1 fiercepharma
November 27, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
Emergent and Valneva's Zika vaccine clears phase 1 fiercepharma
November 26, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
Emergent and Valneva's Zika vaccine clears phase 1 fiercepharma
November 22, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
Under new collaboration, Valneva and Emergent BioSolutions agree to co-develop Zika shot fiercepharma
August 08, 2017
Valneva and Emergent BioSolutions have signed a deal that could be worth about €50 million to develop a Zika vaccine.

Previous page 1 2 3 4 5 Next page